Pfiz­er lifts 2026 guid­ance as can­cer, mi­graine sales off­set Covid slide

Pfizer raised its 2023 profit and revenue forecasts due to strong demand for Eliquis and cancer drug Padcev. It now expects $62B-$64B in sales and $2.95-$3.05 EPS. CEO Albert Bourla cited strong Q3 performance and confidence in the pipeline. The company has invested heavily in acquisitions, including Seagen and Metsera. Pfizer reported Q3 adjusted profit of $0.87 per share, above estimates, with revenue of $16.58B. Eliquis sales rose 25% to $2.52B.

Pfizer (PFE) reported Q3 adjusted EPS of $0.87, beating estimates, and raised full-year revenue guidance to $62-64B. Revenue was $16.58B, down slightly YoY. Key products like Eliquis and Padcev grew, while COVID-related revenue declined. The company confirmed Cecile Guegan as permanent CFO.

Pfizer (PFE) beat Q3 forecasts with adjusted EPS of $0.87 vs. $0.73 expected and revenue of $16.58B vs. $15.87B expected. The company raised its 2026 guidance, citing strong performance in products like Eliquis and Padcev. Pfizer also named Cecile Guegan as permanent CFO.

Pfizer reported a 8% drop in Q3 profits to $3.2B and slight revenue decline to $16.6B, but raised its 2026 forecast to $62-64B. Growth came from acquired products, including Eliquis, Nurtec, and Lorbrena, with sales up 37%. R&D and restructuring costs increased. Shares fell 0.3% in pre-market trading.

Pfizer (PFE) raised its 2023 profit and revenue forecasts after Q3 earnings beat estimates, driven by strong sales of Eliquis and Padcev. Adjusted EPS was $0.87 vs. $0.73 expected, and revenue was $16.58B vs. $15.87B expected. Full-year guidance increased to $2.95-$3.05 EPS and $62B-$64B revenue.

Pfizer reported flat Q3 revenue of $16.6B, raising full-year guidance to $62B-$64B. Eliquis sales grew 25% to $2.52B, offsetting declines in COVID-related products. Adjusted EPS held at $0.87. Shares slipped 0.2% premarket. The company expects Medicare price impacts to be minimal.